| CPC A61K 35/37 (2013.01) [A61K 9/0053 (2013.01); A61K 9/16 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 35/24 (2013.01); A61K 35/74 (2013.01); A61K 35/741 (2013.01); A61K 35/742 (2013.01); A61K 45/06 (2013.01); A61K 47/08 (2013.01); A61K 47/26 (2013.01); A61K 2035/11 (2013.01); Y02A 50/30 (2018.01)] | 9 Claims |
|
1. A method of treating or preventing a recurrent Clostridium difficile infection in a subject in need thereof, the method comprising:
receiving a pharmaceutical composition from a fecal microbiota supply bank,
wherein the fecal microbiota supply bank comprises a plurality of fecal preparations,
wherein each fecal preparation of the plurality comprises non-pathogenic fecal bacteria extracted via standardized processing from a stool of a screened human donor unrelated to the subject,
wherein the pharmaceutical composition comprises saline, a cryoprotectant, and a single fecal preparation from the plurality of fecal preparations, and wherein the non-pathogenic fecal bacteria comprise bacteria of the phylum Firmicutes; and
rectally administering the pharmaceutical composition to the subject, wherein the administering increases the relative abundance of one or more members of the phylum Firmicutes in the intestine of the subject by at least 5% compared to before the administering.
|